# Results Section - Complete Citation Points Analysis

## Citation Density Target
- **Standard:** 1 citation per 3-5 sentences (support/validation/comparison)
- **Word count:** ~1450 words
- **Required citations:** 15-30 citations
- **Current citations:** 4
- **Gap:** 11-26 additional citations needed

---

## Section 1: scRNA-seq Landscape (Lines 1-29)

### Citation Point 1: UMAP dimensionality reduction method
**Line:** "Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction"
**Purpose:** Method validation
**Query:** "UMAP single cell RNA sequencing dimensionality reduction"
**Type:** Method citation

### Citation Point 2: Cell type marker genes validation
**Line:** "Cell type annotation was performed using established marker genes"
**Purpose:** Support marker gene approach
**Query:** "cell type annotation marker genes single cell breast cancer"
**Type:** Support citation

### Citation Point 3: Immune cell infiltration in TNBC
**Line:** "substantially elevated infiltration of immune cells in tumor samples"
**Purpose:** Support/comparison with existing studies
**Query:** "immune cell infiltration triple negative breast cancer"
**Type:** Support citation

### Citation Point 4: T cell differential expression in TNBC
**Line:** "T cells exhibited significant upregulation of IGLV1, TRBV20-1, ATP5E"
**Purpose:** Support/comparison of T cell markers
**Query:** "T cell markers differential expression TNBC"
**Type:** Support citation

### Citation Point 5: GO enrichment analysis method
**Line:** "Gene Ontology (GO) enrichment analysis"
**Purpose:** Method validation
**Query:** "GO enrichment analysis single cell RNA seq"
**Type:** Method citation

### Citation Point 6: Antigen presentation in TNBC ✓ (Already cited: Ref 1, 2)
**Line:** "Antigen processing and presentation pathways...enhanced antigen presentation"
**Current citations:** Sceneay 2019, Gonçalves 2021
**Status:** Adequate

### Citation Point 7: T cell activation pathways
**Line:** "T cell proliferation, lymphocyte mediated immunity, positive regulation of T cell activation"
**Purpose:** Support pathway enrichment findings
**Query:** "T cell activation pathways tumor microenvironment breast cancer"
**Type:** Support citation

### Citation Point 8: Stromal cells in immune regulation ✓ (Already cited: Ref 3)
**Line:** "stromal cells such as Endothelial cells and Fibroblasts, suggesting coordinated regulation"
**Current citation:** Wu 2025
**Status:** Adequate

### Citation Point 9: Metabolic dysfunction in tumor stroma
**Line:** "downregulated genes...metabolic and cellular homeostasis pathways"
**Purpose:** Support metabolic reprogramming in TME
**Query:** "metabolic dysfunction tumor stroma breast cancer"
**Type:** Support citation

### Citation Point 10: Stromal-immune interaction
**Line:** "stromal cell metabolic dysfunction may impact T cell anti-tumor efficacy"
**Purpose:** Support metabolic competition concept
**Query:** "stromal metabolic competition T cell function tumor"
**Type:** Support citation

---

## Section 2: Cell-Cell Communication (Lines 31-43)

### Citation Point 11: CellChat method
**Line:** "ligand-receptor interaction analysis using CellChat"
**Purpose:** Method validation
**Query:** "CellChat ligand receptor interaction analysis"
**Type:** Method citation

### Citation Point 12: Immune cell communication in cancer
**Line:** "increased signaling between immune cells (T cells, B cells, Macrophages)"
**Purpose:** Support enhanced immune crosstalk
**Query:** "immune cell communication tumor microenvironment breast cancer"
**Type:** Support citation

### Citation Point 13: T cell signaling in TNBC
**Line:** "T cells in TNBC exhibited enhanced bidirectional signaling"
**Purpose:** Support T cell signaling alterations
**Query:** "T cell signaling triple negative breast cancer"
**Type:** Support citation

### Citation Point 14: MHC-I pathway alterations
**Line:** "unique alterations in MHC-I, MIF, and CD99 pathways"
**Purpose:** Support MHC-I changes in TNBC
**Query:** "MHC class I expression triple negative breast cancer"
**Type:** Support citation

### Citation Point 15: MIF signaling in T cell recruitment
**Line:** "MIF-(CD74+CD44), MIF-(CD74+CXCR4)"
**Purpose:** Support MIF-CD74 axis in immune response
**Query:** "MIF CD74 T cell recruitment tumor"
**Type:** Support citation

### Citation Point 16: CXCL chemokine signaling
**Line:** "CXCL12-CXCR4, and CXCL10-CXCR3"
**Purpose:** Support chemokine-mediated T cell recruitment
**Query:** "CXCL12 CXCR4 CXCL10 CXCR3 T cell migration tumor"
**Type:** Support citation

### Citation Point 17: Macrophage-T cell crosstalk
**Line:** "CXCL10-CXCR3 may serve as a specific communication pathway between Macrophages and T cells"
**Purpose:** Support macrophage-T cell interaction
**Query:** "CXCL10 CXCR3 macrophage T cell crosstalk"
**Type:** Support citation

---

## Section 3: Ubiquitination-Related Genes (Lines 45-53)

### Citation Point 18: Ubiquitination in cancer ✓ (Already cited: Ref 4)
**Line:** "ubiquitination profoundly influences cellular growth, differentiation, cell cycle regulation"
**Current citation:** Chen 2024
**Status:** Adequate

### Citation Point 19: WGCNA method
**Line:** "Weighted gene co-expression network analysis (WGCNA)"
**Purpose:** Method validation
**Query:** "WGCNA weighted gene coexpression network analysis cancer prognosis"
**Type:** Method citation

### Citation Point 20: WGCNA module-trait correlation
**Line:** "MEturquoise module exhibited the strongest correlation with survival time"
**Purpose:** Support prognostic module identification
**Query:** "WGCNA module survival correlation cancer"
**Type:** Support citation

### Citation Point 21: Multi-omics integration approach
**Line:** "Integration with Kaplan-Meier survival analysis...and univariate Cox regression"
**Purpose:** Support integrated analytical approach
**Query:** "integrated analysis Kaplan Meier Cox regression biomarker identification"
**Type:** Support citation

---

## Section 4: Risk Model Construction (Lines 55-61)

### Citation Point 22: LASSO-Cox regression method
**Line:** "LASSO-Cox regression analysis"
**Purpose:** Method validation
**Query:** "LASSO Cox regression cancer prognosis biomarker selection"
**Type:** Method citation

### Citation Point 23: Gene signature validation strategy
**Line:** "partitioned the TCGA dataset into training and test sets"
**Purpose:** Support validation strategy
**Query:** "training test validation prognostic signature cancer"
**Type:** Method citation

### Citation Point 24: KRT8 in cancer progression
**Line:** "KRT8 and OTUB1 were significantly upregulated in the high-risk group"
**Purpose:** Support KRT8 oncogenic role
**Query:** "KRT8 keratin 8 cancer progression prognosis"
**Type:** Support citation

### Citation Point 25: OTUB1 in cancer
**Line:** "OTUB1 were significantly upregulated in the high-risk group"
**Purpose:** Support OTUB1 role in cancer
**Query:** "OTUB1 deubiquitinase cancer prognosis"
**Type:** Support citation

### Citation Point 26: GMCL1 tumor suppressor
**Line:** "GMCL1 exhibited the opposite pattern"
**Purpose:** Support GMCL1 protective role
**Query:** "GMCL1 tumor suppressor cancer"
**Type:** Support citation

---

## Section 5: Clinical Validation (Lines 63-73)

### Citation Point 27: Time-dependent ROC analysis
**Line:** "time-dependent ROC curve analysis"
**Purpose:** Method validation
**Query:** "time dependent ROC curve survival prediction"
**Type:** Method citation

### Citation Point 28: AUC interpretation standards
**Line:** "AUC values for 2-year, 3-year, and 5-year survival predictions"
**Purpose:** Support AUC performance benchmarks
**Query:** "AUC interpretation prognostic model cancer"
**Type:** Method citation

### Citation Point 29: Multivariate Cox regression
**Line:** "multivariate Cox regression confirmed the risk score as an independent prognostic factor"
**Purpose:** Support independent prognostic value
**Query:** "multivariate Cox regression independent prognostic factor cancer"
**Type:** Method citation

### Citation Point 30: Clinical nomogram construction
**Line:** "constructed a nomogram incorporating age, T stage, grade, N stage, and risk score"
**Purpose:** Support nomogram approach
**Query:** "nomogram prognostic prediction breast cancer"
**Type:** Support citation

### Citation Point 31: Calibration curve validation
**Line:** "Calibration curves validated the nomogram's robust predictive performance"
**Purpose:** Method validation
**Query:** "calibration curve nomogram validation"
**Type:** Method citation

### Citation Point 32: Nomogram superiority
**Line:** "nomogram achieved superior predictive performance (AUC = 0.719) compared to individual clinical factors"
**Purpose:** Support integrated model superiority
**Query:** "nomogram superior prognostic accuracy clinical factors cancer"
**Type:** Support citation

---

## Summary

**Total Citation Points Identified:** 32
**Already Cited:** 4 (Points 6, 8, 18 + general ref 4)
**Additional Citations Needed:** 28

**Citation Distribution:**
- Method citations: 12 (UMAP, markers, GO, CellChat, WGCNA, LASSO-Cox, ROC, etc.)
- Support citations: 16 (immune infiltration, pathways, signaling, gene functions, etc.)
- Validation citations: 4 (model validation, performance benchmarks)

**Next Action:** Execute literature search for all 28 citation points in batches
